Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
Aims The aim of this study was to achieve consensus for important topics related to periprosthetic infection (PJI) in orthopaedic oncology, and to identify areas for future research. Methods In January 2024, the Birmingham Orthopaedic Oncology Meeting (BOOM) held in Birmingham, UK, gathered 309 delegates from 53 countries to debate 20 consensus statements on PJI in orthopaedic oncology using a modified Delphi process. Results Of 20 questions and statements on PJI in orthopaedic oncology, none achieved unanimous consensus, 18 achieved strong consensus, one achieved moderate consensus, and one achieved weak consensus. The statements that reached consensus with notable agreement were on the prophylaxis of infection, management of leaking wounds, and surgical strategies for the treatment of PJI. Short-duration antibiotic prophylaxis was deemed as effective as longer courses for lower-risk reconstructions, and aggressive management was recommended for wounds draining beyond five to seven days to prevent deep infection. Furthermore, single-stage, two-stage, and 1.5-stage revision were recognized as valid strategies, with two-stage revision remaining the most reliable. The statements that did not achieve consensus were on the role of debridement, antibiotics, and implant retention and prolonged antibiotic use post-revision. Conclusion The BOOM meeting achieved consensus for important topics on periprosthetic infection in orthopaedic oncology, but highlighted the low quality of the underlying evidence. This study has provided recommendations for the treatment of leaky wounds, duration of postoperative antibiotic prophylaxis, and choice of revision strategy.
A modified Delphi consensus on periprosthetic infection in orthopaedic oncology
Lee Jeys;Eduardo Botello;Richard A Boyle;Walid Ebeid;Matthew T Houdek;Vineet J Kurisunkal;Rhidian Morgan-Jones;Guy V Morris;Ajay Puri;Pietro Ruggieri;Minna K Laitinen;Santiago Abad Repiso;Hesham Abdelbary;Alejandro Abiad Mejia;Ahmed A Abood;Ghaith Abou-Nouar;Juan C Abril Martin;Ayman Abu Elhamd;Adesegun Abudu;Marthelena Acosta;Keisuke Ae;Manish Agarwal;Vivek Ajit Singh;Toru Akiyama;Jose I Albergo;John Alexander;Patricio A Alfaro;Bugra Alpan;Ibrahim Alshaygy;Jose Amaya-Valero;Megan Anderson;Dimosthenis Andreou;Lucas Annabell;Christopher Anthony;Ahmed Aoude;Iraia Arteagoitia-Colino;Apichat Asavamongkolkul;William Aston;Libe Asua Mentxaka;Christine Azzopardi;Thomas Baad-Hansen;Ismail T Badr;Francisco Baixauli-Garcia;Gavin Baker;Tessa Balach;Giacomo G Baldi;Janie Barry;Georges Basile;Stefano Bastoni;Mohammad Hardian Basuki;Henrik Bauer;Lee Bayliss;Ricardo G Becker;Angad Bedi;Joseph Benevenia;Francisco Bengoa;Peter Bergh;Marko Bergovec;Nicholas Bernthal;Odion Binitie;David Boddie;Michele Boffano;Patricia Bonilla Huertas;Anna B Borgognoni;Rajesh Botchu;Jos Bramer;Harriet Branford-White;Rahat Brar;Demien Broekhuis;Samuel E Broida;Tymoteusz Budny;Zachary Dc Burke;Jorge Cabrolier;Jorge R Calvo Tapies;Jose A Calvo-Haro;Dominico Campanacci;Rodrigo Cardoso;Richard Carey Smith;Pedro I Carvallo;Nicolas Casales Fresenga;Jose Manuel Casanova;Oscar Ceballos;Juan Luis Cebrian Parra;Laura K Certain;Sara Chacon Cartaya;Chung Ming Chan;Yoon Joo Cho;Peter Choong;Yang-Guk Chung;Dawid Ciechanowicz;Miguel Angel Clara-Altamirano;David Clever;Sebastian Matheo Colina;Luis Consuegra;Cory Couch;Gillian Cribb;Carlos Cuervo;Laurence A Cusick;Solomon Dadia +;Tanios Dagher;Dietmar Dammerer;Mark Davies;Nerys Davies;Luis Pablo de la Rosa Martino;Francisco Javier de Santos de la Fuente +;Marieke de Vaal;Claudia Deckers;Javier Delgado Obando;Shaneel Deo;Niklas Deventer;Claudia Di Bella;Gregory Domson;Davide Maria Donati;Desiree M Dorleijn;Jacques Du Toit;Debra Dunne;Rodolfo Duran Ciarrochi;Elina Ekman;Ahmed M El Ghoneimy;Makoto Endo;Levent Eralp;Mahmoud Etaiwi;Scott Evans;Robin Evrard;Will Eward;Alberto Farese;Peter C Ferguson;Pedro Filipe Ferreira Cardoso;Fabrice Fiorenza;Michael Flint;Hector Flores;Joao Freitas;Bruno Fuchs;Tomohiro Fujiwara;Philipp T Funovics;Marcos Galli Serra;Zakareya Gamie;Carlos Garces-Zarzalejo;Aaron Gazendam;Carsten Gebert;Jasper G Gerbers;Craig Gerrand;Michelle Ghert;Kanishka M Ghosh;Max Gibbons;Anne Gomez-Mascard;Luis Carlos Gomez-Mier;Jesus Gomez-Vallejo;Marcos R Gonzalez;Fausto Gonzalez-Lizan;Georg Gosheger;Stuart Goudie;Krista Goulding;Stavros D Goumenos;Anthony Griffin;Ashish Gulia;Sanjay Gupta;Amit Gupta;Maurice Guzman;Mohammed Haitham;Jendrik Hardes;Francisco Hardoy;Yusuf Hasan;Georg Hauer;Helard Havard;Rex Haydon;John Healey;Nerea Hernandez Gonzalez;Adriana Hernandez-Lopez;Asle Hesla;Matthew Hess;Thomas Hilton;Chindanai Hongsaprabhas;Francis Hornicek;Keith Hosking;Eleanor Houghton;Oluwaseyi K Idowu;Joseph Ippolito;Marc Isler;Shintaro Iwata;Jake Jagiello;Neil Jenkins;Tom Jeys;Charlotte Jeys;Luke Johnson;Andy Johnston;Min Wook Joo;Paul C Jutte;Kadri Kaldas;Amar Kamat;Sudhir Kannan;Bilal Kapanci;Zeeshan Khan 151;Hiroshi Kobayashi 152;Yehuda Kollender;Sebastian Koob;Daniel Kotrych;Richard Kyte;Jose Maria Lamo de Espinosa Vazquez de Sola 156;Alexander L Lazarides 53;Louis-Romee Le Nail;Pawel Legosz;Burkhard Lehner;Andreas Leithner 135;Maryse Lejoly;Valerae O Lewis;Peng Lin 162;Francisco Linares 163;Santiago Lozano-Calderon;Ashish Mahendra;Ferdiansyah Mahyudin 164;Fermin Julian Mandia Mancebo;Sara Martos Torrejon 166;Christian Marx 145;Eric Mascard;Jean-Camille Mattei;Louise McCullough;Sam McMahon;Manuel Ricardo Medellin Rincon;Benjamin Miller 171;Shinji Miwa 172;Gustavo Molina Uribe 173;Bryan Moon 161;Diego Jesus Moriel Garcesco;Carol Morris;Stewart Morrison;Sophie Mottard 42;Marcio Moura 175;Linde Muster 176;Robert Nakayama 177;Prashant Narhari;Ana Navas;Prakash Nayak;Johannes Neugebauer 180;Erik T Newman 125;Jyrki Nieminen 181;Emmy Nyqvist 45;Lukas Nystrom 182;Sarah O'Reilly-Harbidge;Gary O'Toole;Vania Oliveira 185;André Olivier 186;Mohamed Omar 187;Eduardo J Ortiz-Cruz 188;Harzem Ozger 189;Korhan Ozkan;Elisa Pala;Emanuela Palmerini;Grant Pang;Panayiotis Papagelopoulos 129;Giovanni Paraliticci 192;Michael C Parry 1;Sam Patton 127;David Peake 1;Ana Peiro Ibanez 193;Israel Perez Munoz 194;Ganapathy Raman Perianayagam 195;Michael Mork Petersen 196 197;Joris Ploegmakers 47;Robin Pollock 31;Gerard Powell 95;Juan Pretell 192;Jan Puetzler 62;Faisal Qamar 198;Anand Raja 199;Raja Bhaskara Rajasekaran 200;Dipak B Ramkumar 201;R Lor Randall 202;Kenneth S Rankin 197;Kevin A Raskin 125;Kumaran Rassppan 1 203;Lauris Repsa 204;Mickael Ropars 205;Peter Rose 61;Wael Sadek 16;German Salcedo 206;Aasim Saleemi 207;Andrea Sambri 208;Hartej Sar 1;Roberto Scanferla 209;Thomas Schubert 210;Jan Schwarze 62;Guido Scoccianti 211;Ashley Scrimshire 203;Tetsuya Sekita 144;Ahmad Shehadeh 212;Ahmed Shoaib 213;Bhim Shreemal 1;Felix Shumelinsky 150;Geoffrey Siegel 214;Claudio Silveri 215;Robert Silverwood 131;Friedl Sinnaeve 216;Jerome Sison 1;Andrea Slade 1;Maria Anna Smolle 135;Franz Snyman 217;Scott Sommerville 218;Sahil Sood 219;Andre Spiguel 220;Hugo St-Yves 42;Eric L Staals 97;Silvia Stacchiotti 221;Nikolaos Stavropoulos 222;Peter Steadman 223;Jonathan D Stevenson 1;Mikaela Sullivan 61;Gwen Sys 98;Bartlomiej Szostakowski 224;Angela Tamburini 225;Yuta Taniguchi 172;Thomas Temple 141;Christoph Theil 62;Joachim Thorkildsen 226;Meagan Tibbo 227;Roger Tillman 1;Yu Toda 144;Kaspar Tootsi 228;Ferran Torner Rubies 229;Frank Traub 230;Ioannis Trikoupis 129;Panagiotis Tsagkozis 45;Kim Tsoi 83;Hiroyuki Tsuchiya 172;Veli-Matti Vainio 231;Antonio Valcarcel 232;Juan Valencia 233;Annelies Van Beeck 234;Michel Van de Sande 235;Thomas Van Den Berghe 160;Ingrid Van der Geest 92;Lizz Van der Heijden 236;Robert Van der Wal 60;Kirsten Van Langevelde 60;Gualter Vaz 237;Roberto Velez Villa 238;Floortje Verspoor 239;Koenraad Verstraete 240;Julia Visgauss 107;Oleg Vyrva 241;Hazem Wafa 242;Sebastian Walter 243;Wan Faisham Wan Ismail 244;Edward Wang 245;Patrick Qi Wang 42;David Warnock 39;Joel Werier 11;Wolfram Weschenfelder 246;Kwok-Chuen Wong 247;Marjan Woulthuyzen-Bakker 248;Jay Wunder 83;Indica Wysinghe 1;Norio Yamamoto 172;Zhaoming Ye 162;Seung-Jae Yoon 249;Suraya Zainul Abidin 250;Tomas Zamora 251;Pierluca Zecchetto 252;Liuzhe Zhang 83;Juan Pablo Zumarraga
2025
Abstract
Aims The aim of this study was to achieve consensus for important topics related to periprosthetic infection (PJI) in orthopaedic oncology, and to identify areas for future research. Methods In January 2024, the Birmingham Orthopaedic Oncology Meeting (BOOM) held in Birmingham, UK, gathered 309 delegates from 53 countries to debate 20 consensus statements on PJI in orthopaedic oncology using a modified Delphi process. Results Of 20 questions and statements on PJI in orthopaedic oncology, none achieved unanimous consensus, 18 achieved strong consensus, one achieved moderate consensus, and one achieved weak consensus. The statements that reached consensus with notable agreement were on the prophylaxis of infection, management of leaking wounds, and surgical strategies for the treatment of PJI. Short-duration antibiotic prophylaxis was deemed as effective as longer courses for lower-risk reconstructions, and aggressive management was recommended for wounds draining beyond five to seven days to prevent deep infection. Furthermore, single-stage, two-stage, and 1.5-stage revision were recognized as valid strategies, with two-stage revision remaining the most reliable. The statements that did not achieve consensus were on the role of debridement, antibiotics, and implant retention and prolonged antibiotic use post-revision. Conclusion The BOOM meeting achieved consensus for important topics on periprosthetic infection in orthopaedic oncology, but highlighted the low quality of the underlying evidence. This study has provided recommendations for the treatment of leaky wounds, duration of postoperative antibiotic prophylaxis, and choice of revision strategy.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3570458
Citazioni
2
1
1
1
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.